2022
Nanoparticle-based drug delivery for the treatment of traumatic brain injury
Mohammed F, Omay S, Sheth K, Zhou J. Nanoparticle-based drug delivery for the treatment of traumatic brain injury. Expert Opinion On Drug Delivery 2022, 20: 55-73. PMID: 36420918, PMCID: PMC9983310, DOI: 10.1080/17425247.2023.2152001.Peer-Reviewed Original ResearchConceptsTraumatic brain injuryBrain injurySecondary outcomesClinical trialsPathophysiology of TBIPhase III clinical trialsPhase II clinical trialClinical management strategiesSite of injuryOff-target toxicityPharmacological treatmentBrain penetrationLow off-target toxicityExperimental animalsInjuryChronic timescalesDosage thresholdDrug deliveryTrialsDrug targetingOutcomesTreatmentDeliveryPathophysiologyThe Stroke Preclinical Assessment Network: Rationale, Design, Feasibility, and Stage 1 Results
Lyden PD, Bosetti F, Diniz MA, Rogatko A, Koenig JI, Lamb J, Nagarkatti KA, Cabeen RP, Hess DC, Kamat PK, Khan MB, Wood K, Dhandapani K, Arbab AS, Leira EC, Chauhan AK, Dhanesha N, Patel RB, Kumskova M, Thedens D, Morais A, Imai T, Qin T, Ayata C, Boisserand LSB, Herman AL, Beatty HE, Velazquez SE, Diaz-Perez S, Sanganahalli BG, Mihailovic JM, Hyder F, Sansing LH, Koehler RC, Lannon S, Shi Y, Karuppagounder SS, Bibic A, Akhter K, Aronowski J, McCullough LD, Chauhan A, Goh A, Siddiqui S, Sheth K, Matouk C, Cruz C, Zhou J, Dawson V, Dawson T, Liang J, van Zijl P, Zeiler S, Taylor Kimberly W, Erdogan T, Yu L, Mandeville J, Whittier J. The Stroke Preclinical Assessment Network: Rationale, Design, Feasibility, and Stage 1 Results. Stroke 2022, 53: 1802-1812. PMID: 35354299, PMCID: PMC9038686, DOI: 10.1161/strokeaha.121.038047.Peer-Reviewed Original ResearchConceptsPreclinical assessmentStroke treatmentCandidate treatmentMiddle cerebral artery occlusion (MCAO) surgeryClinical stroke trialsSuccessful stroke treatmentInclusion/exclusion criteriaStroke clinical trialsClinical trial designYoung male animalsComorbid diseasesOcclusion surgeryCerebral ischemiaNeurological disabilityComorbid conditionsStroke trialsProtocol adherenceBlinded assessmentSuch therapyClinical trialsClinical studiesExclusion criteriaTrial designAged animalsOutcome assessment
2021
How to Establish the Outer Limits of Reperfusion Therapy
Wechsler L, Jadhav A, Jovin T, Adeoye O, Albers G, Ansari S, Boltze J, Buchan A, Campbell B, Chaisinanunkul N, Chen C, Derdeyn C, Haddad W, Hill M, Holt W, Houser G, Khatri P, Krtolica A, Landen J, Lansberg M, Liebeskind D, Lyden P, Lynch J, Meinzer C, Mistry E, Mocco J, Nogueira R, Saver J, Savitz S, Schwamm L, Sheth K, Snyder M, Solberg Y, Vagal A, Venkatasubramanian C, Warach S, Ziogas N. How to Establish the Outer Limits of Reperfusion Therapy. Stroke 2021, 52: 3399-3403. PMID: 34470484, DOI: 10.1161/strokeaha.121.035022.Peer-Reviewed Original ResearchConceptsReperfusion therapyAcute ischemic strokeLarge pragmatic trialRoutine clinical practiceDrug Administration approvalTreatment effectsIntravenous alteplaseIschemic strokeStroke onsetEndovascular therapyRandomized trialsPragmatic trialImaging featuresAdministration approvalPlatform trialsSignificant treatment effectEffective treatmentTreatment efficacyAcademic centersClinical practiceTherapyPatientsTrialsMedical communityStatistical significanceTop Priorities for Cerebroprotective Studies—A Paradigm Shift
Lyden P, Buchan A, Boltze J, Fisher M, Ansari S, Broderick J, Campbell B, Chaisinanunkul N, Chen C, Grotta J, Haddad W, Hareedy R, Hill M, Houser G, Jadhav A, Khatri P, Kimberly W, Koenig J, Korinek W, Landen J, Lansberg M, Latour L, Liebeskind D, Liston T, Lynch J, McGonigle J, Mistry E, Mocco J, Pryor K, Saver J, Savitz S, Sheth K, Solberg Y, Vagal A, Venkatasubramanian C, Ziogas N. Top Priorities for Cerebroprotective Studies—A Paradigm Shift. Stroke 2021, 52: 3063-3071. PMID: 34289707, PMCID: PMC8384700, DOI: 10.1161/strokeaha.121.034947.Peer-Reviewed Original ResearchConceptsComprehensive preclinical assessmentPreclinical assessmentNeurovascular unitMajor public health concernSalvageable brain tissueStroke symptom onsetIschemic stroke treatmentBlood-brain barrierConsensus-based recommendationsPharmacokinetics/pharmacodynamicsClinical trial designPaucity of evidencePublic health concernDifferent brain regionsMechanism of actionCerebroprotective agentTerm neuroprotectionIschemic strokeSymptom onsetStroke treatmentClinical outcomesComorbid conditionsCore injuryClinical trialsStroke model
2018
Basic and Translational Research in Intracerebral Hemorrhage
Selim M, Hanley D, Broderick J, Goldstein J, Gregson B, Falcione G, Gonzales N, Gurol E, Kersten J, Lewkowicz H, Mendelow A, Muehlschlegel S, Neuman R, Palesch Y, Rosenblum M, Sheth K, Singh V, Ziai W, Keep R, Aronowski J, Genstler C, James M, Ratan R, Sansing L, Youd A, Xi G, Zille M, Anderson C, Awad I, Bastings E, Bednar M, Coon A, Gottesman R, Katz B, Khan S, Koenig J, Koroshetz W, Ling S, Loftus C, Lockhardt J, Louis T, Marler J, Moy C, Peña C, Pollack C, Omert L, Shah M, Shoamanesh A, Singer M, Steiner T, Torbey M, Tymianski M, Wakhloo A, Vespa P, Zuccarello M, Zheng X. Basic and Translational Research in Intracerebral Hemorrhage. Stroke 2018, 49: 1308-1314. PMID: 29618555, PMCID: PMC5915965, DOI: 10.1161/strokeaha.117.019539.Peer-Reviewed Original Research
2017
Brain Ischemia Suppresses Immunity in the Periphery and Brain via Different Neurogenic Innervations
Liu Q, Jin WN, Liu Y, Shi K, Sun H, Zhang F, Zhang C, Gonzales RJ, Sheth KN, La Cava A, Shi FD. Brain Ischemia Suppresses Immunity in the Periphery and Brain via Different Neurogenic Innervations. Immunity 2017, 46: 474-487. PMID: 28314594, DOI: 10.1016/j.immuni.2017.02.015.Peer-Reviewed Original ResearchConceptsPost-stroke infectionsBrain ischemiaMiddle cerebral artery occlusionCell-mediated immune defenseAdrenal axis leadsNK cell numbersCerebral artery occlusionNK cell responsesNK cell functionNatural killer cellsExpression of SOCS3Infectious complicationsArtery occlusionImmune alterationsIschemic strokeSplenic atrophyKiller cellsImmune functionCell responsesGenetic ablationIschemiaImmune defenseBrainCell functionInnervation
1999
Purification of serine racemase: Biosynthesis of the neuromodulator d-serine
Wolosker H, Sheth K, Takahashi M, Mothet J, Brady R, Ferris C, Snyder S. Purification of serine racemase: Biosynthesis of the neuromodulator d-serine. Proceedings Of The National Academy Of Sciences Of The United States Of America 1999, 96: 721-725. PMID: 9892700, PMCID: PMC15203, DOI: 10.1073/pnas.96.2.721.Peer-Reviewed Original ResearchConceptsBiosynthetic pathwayD-serine occursSerine racemaseAmino acidsD-serineMammalian brainNeuromodulator D-serineL-serineMolecular massSoluble enzymeEndogenous ligandPyridoxal phosphateRat brainN-methyl-D-aspartate receptorsEnzymeKm valuesRacemasePathwayHigh levelsRat cerebral cortexAspartate glutamate receptorsGlutamate receptorsRacemasesType II astrocytesGlial cultures